Sequella is a private, clinical-stage pharmaceutical company that addresses the challenge of antibiotic-resistant bacterial diseases by discovery, development, and commercialization of first-in-class antibiotics with novel mechanisms of action. Our lead drug candidate identified from our current >150,000 proprietary compound library, SQ109, is in Phase 2 clinical trials for treatment of both tuberculosis (TB) and gastritis (Helicobacter pylori infections), diseases complicated by growing resistance to existing drugs. In 2013, we acquired a new clinical-stage (Phase 2) oxazolidinone, sutezolid, for treatment of TB and other resistant bacterial diseases. We also have a vigorous research program to develop novel antibiotics that target the enzyme translocase-1, an essential enzyme in all bacteria. Our product portfolio addresses global health threats with significant market opportunity in disease areas of known or suspected infectious etiology: * TB (Mycobacterium tuberculosis) * Duodenal ulcers (Helicobacter pylori) * Gastric carcinomas (Helicobacter pylori) * CDI (Clostridium difficile) * Crohn’s Disease (Mycobacterium avium paratuberculosis) * Chagas Disease (Trypanosoma cruzi)
View Top Employees from Sequella, Inc.Website | http://www.sequella.com |
Revenue | $7 million |
Funding | $11.9 million |
Employees | 6 (4 on RocketReach) |
Founded | 1997 |
Address | 9610 Medical Center Dr Ste 200, Rockville, Maryland 20850, US |
Phone | (301) 762-7776 |
Fax | (301) 762-7778 |
Technologies |
JavaScript,
Google Analytics,
ASP.NET
+3 more
(view full list)
|
Industry | Biotechnology Research, Manufacturing General, Biotechnology, Drug Discovery, Manufacturing, Science and Engineering, Pharmaceuticals, Developer Platform, Software, Health Care |
Web Rank | 10 Million |
Keywords | Sequella Inc, Sequella Inc., Sequella |
Competitors | AZTherapies, Cempra Pharmaceuticals, Nabriva Therapeutics plc, Soligenix, Inc., Tetraphase Pharmaceuticals |
SIC | SIC Code 28 Companies, SIC Code 283 Companies |
NAICS | NAICS Code 3254 Companies, NAICS Code 32541 Companies, NAICS Code 325 Companies, NAICS Code 32 Companies |
Looking for a particular Sequella, Inc. employee's phone or email?
The Sequella, Inc. annual revenue was $7 million in 2024.
Lisa Ferstenberg is the Medical Director of Sequella, Inc..
4 people are employed at Sequella, Inc..
Sequella, Inc. is based in Rockville, Maryland.
The NAICS codes for Sequella, Inc. are [3254, 32541, 325, 32].
The SIC codes for Sequella, Inc. are [28, 283].